Five drugs were approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive BC, known as trastuzumab, pertuzumab, TDM-1, lapatinib, and neratinib (6–10). The gene discussed is ERBB2; the disease is breast cancer.